476 results on '"Burwick, Richard"'
Search Results
102. 600: Smoldering thrombotic microangiopathy in preeclampsia
103. 320: Marijuana use in women with a hypertensive disorder of pregnancy: Is it safe?
104. Reply to N. Cerveira et al
105. 803: Maternal and Neonatal morbidity after four and six hours of protracted active labor
106. 598: Assessment of blood-brain-barrier integrity and neuroinflammation in preeclampsia
107. 599: Pregnancy-associated atypical hemolytic uremic syndrome: some answers
108. 711: Pregnancy outcomes in current versus prior tobacco users in women with hypertension and preeclampsia
109. 506: A population-based definition for severe proteinuria and its association with adverse outcomes in preeclampsia
110. 1023: Autonomic regulation of maternal heart rate variability in preeclampsia
111. Association between insurance type and pregnancy outcomes in women diagnosed with hypertensive disorders of pregnancy.
112. Association between insurance type and pregnancy outcomes in women diagnosed with hypertensive disorders of pregnancy
113. Reply to D.M. Ross et al and V. Florou et al
114. Treatment of Iron Deficiency Anemia in Pregnancy with Intravenous versus Oral Iron: Systematic Review and Meta-Analysis
115. Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy
116. 640: Impact of insurance status on outcomes in women with hypertensive disorders in pregnancy
117. 306: Preeclampsia with severe features, defining a subset of women with complement-associated disease
118. 329: Excess complement activation is associated with adverse outcomes in women with hypertensive disorders of pregnancy
119. 305: Increased complement activation in preeclampsia, a strong association with severe disease
120. 67: Improved diagnosis of preeclampsia with severe features and end organ injury using complement activation measurement in urine and plasma
121. 307: Hemolysis, a severe feature of preeclampsia
122. Fetal hydrops and the risk of severe preeclampsia
123. The Complement System and Preeclampsia
124. 439: The impact of preeclampsia with severe features on neonatal outcomes by gestational age
125. 849: Cost-effectiveness of exercise for the prevention of preeclampsia and gestational diabetes in normal weight women
126. 440: Cost-effectiveness of exercise for the prevention of preeclampsia and gestational diabetes in obese women
127. 875: Chronic hypertension and pregnancy: does race affect outcomes?
128. Fetal hydrops and the risk of severe preeclampsia.
129. Situs inversus totalis and prenatal diagnosis of a primary ciliary dyskinesia.
130. Pregnancies complicated by both preeclampsia and growth restriction between 34 and 37 weeks’ gestation are associated with adverse perinatal outcomes
131. 756: Fetal hydrops and the risk of adverse maternal outcomes
132. 622: Preeclampsia with severe features: evaluation of the new ACOG criteria in a contemporary cohort
133. 283: Congenital anomalies in twin versus triplet pregnancies
134. 481: Predictors of developing severe maternal morbidities of preeclampsia
135. Evaluation of Hemolysis as a Severe Feature of Preeclampsia.
136. Response: Maternal and cord C5a in response to eculizumab
137. Maternal and feto-placental phenotypes of early-onset severe preeclampsia
138. 423: Does fetal growth restriction predict adverse maternal and neonatal outcomes in women with preeclampsia?
139. 533: Chronic hypertension & severe, early onset preeclampsia
140. 861: Fetal hydrops and the risk of severe preeclampsia
141. 882: Outcomes of term pregnancies complicated by gestational diabetes mellitus and polyhydramnios
142. 860: Polyhydramnios, an independent risk factor for preeclampsia
143. 723: Outcomes of late preterm pregnancies complicated by gestational diabetes mellitus and polyhydramnios
144. 379: Chronic hypertension increases risk for all preeclampsia phenotypes
145. 24: Polyhydramnios & risk of fetal death
146. Urinary Excretion of C5b-9 is Associated With the Anti-Angiogenic State in Severe Preeclampsia
147. Pregnancies complicated by both preeclampsia and growth restriction between 34 and 37 weeks' gestation are associated with adverse perinatal outcomes.
148. Eculizumab fails to inhibit generation of C5a in vivo
149. Complement Activation and Kidney Injury Molecule-1–Associated Proximal Tubule Injury in Severe Preeclampsia
150. Indomethacin and Antibiotics in Examination-Indicated Cerclage
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.